A decision-tree model was developed to estimate the incremental cost-effectiveness of companion BRCA testing and olaparib use versus no testing and the standard of care (SoC) for patients with BRCA-mutated high-risk HER2-negative early breast cancer from a UK NHS/PSS perspective. This evidence concerns the gene ERBB2 and breast cancer.